3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Sponsor: Lahey Clinic
ClinicalTrials ID:NCT00872950
This open-label, non-randomized study evaluates 3,4-diaminopyridine in up to 25 patients with LEMS or CMS. Participants, aged 18+, must meet specific diagnostic criteria and have no prolonged QT syndrome. Treatment starts at a low dose, titrating up to 100mg/day based on efficacy and tolerance. Female participants require a negative pregnancy test and effective birth control.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).
Description
This is an open-label, non-randomized, non-comparative expanded access study. Up to 25 patients with clinically proven paraneoplastic or primary autoimmune LEMS per EMG and positive voltage-gated calcium channel antibody serology, OR patients with clinically proven CMS per electromyogram (EMG), biopsy or genetic testing who meet the selection criteria outlined in sections 3.1 and 3.2 will be enrolled in this study. Subjects will receive 3,4-diaminopyridine (3,4-DAP) starting with a low dose and titrating up per efficacy and patient tolerance to a maximum daily dose of 100mg . Treatment will continue until the subject experiences a treatment-limiting toxicity, voluntarily withdraws consent, transfers to another site, dies, becomes lost to follow-up, is no longer receiving clinical benefit from 3,4-DAP (in the opinion of the subject and/or the investigator), or the Jacobus Pharmaceuticals or the FDA discontinues the study.
Eligibility Criteria
Inclusion Criteria
- LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis
- 18 years or older
- Females must have negative pregnancy test and be willing to practice an effective form of birth control
- No prolonged QT syndrome as indicated by baseline EKG
Exclusion Criteria
- Known sensitivity to 3,4-DIAMINOPYRIDINE
- History of seizures and/or severe asthma
Get This Program In Your Inbox
You can sign up and apply your patients for this program.